Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
Fiche publication
Date publication
janvier 2020
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MENNECIER Bertrand
Tous les auteurs :
Domblides C, Leroy K, Monnet I, Mazières J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart AC, Audigier-Valette C, Doucet L, Giroux-Leprieur E, Guisier F, Ricordel C, Molinier O, Perol M, Pichon E, Robinet G, Templement-Grangerat D, Ruppert AM, Rabbe N, Antoine M, Wislez M
Lien Pubmed
Résumé
Immune checkpoint inhibitors (ICI) have improved cancer prognosis, but have not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype with poor prognosis. As such, our study sought to retrospectively assess the ICI efficacy in SC.
Mots clés
Immune Check Point Inhibitor, PD-L1, Pulmonary sarcomatoid carcinoma, Tumor Mutational Burden
Référence
J Thorac Oncol. 2020 Jan 25;: